Focal Segmental Glomerulosclerosis Market

Q: How big was the focal segmental glomerulosclerosis market in 2025?

It was valued at US$ 1.2 Bn in 2025 Read More

Q: Which was the major region in the global focal segmental glomerulosclerosis landscape in 2025?

North America was the leading region in 2025 Read More

Focal Segmental Glomerulosclerosis Market (Disease Type: Primary Focal Segmental Glomerulosclerosis and Secondary Focal Segmental Glomerulosclerosis; and Disease Management: Diagnosis and Treatment) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, , 2026-2036

Focal Segmental Glomerulosclerosis Market Outlook 2036

The global industry was valued at US$ 1.2 Bn in 2025
It is estimated to advance at a CAGR of 5.8% from 2026 to 2036 and reach US$ 2.3 Bn by the end of 2036

Focal Segmental Glomerulosclerosis Market By Revenue

Analyst Viewpoint

Increase in prevalence of kidney infection is one of the key factors boosting the global focal segmental glomerulosclerosis market size. A person suffering from kidney disease is at higher risk of contracting focal segmental glomerulosclerosis, as both kidney diseases and focal segmental glomerulosclerosis are interrelated. Advancements in R&D are also augmenting the focal segmental glomerulosclerosis industry growth. Various treatments are being developed for focal segmental glomerulosclerosis, including stem cell therapy and genetic therapies.

Companies in the global landscape are striving to develop specialized diagnostic tests and treatments to improve the prognosis of patients with this disease. In line with the latest focal segmental glomerulosclerosis market, key players are also engaged in product launches and product approvals to increase their industry share.

Market Introduction

Focal segmental glomerulosclerosis (FSGS) is a type of kidney disease characterized by the formation of scar tissue on the glomeruli, the filtering part of the kidney that eliminates waste from the body.

FSGS causes aberrant protein loss in the urine and impairment in the kidneys' filtration capacity. The condition is most commonly characterized by frothy urine, excessive water retention, infection susceptibility, and fatty casts in the urine.

Some of the common causes of FSGS are kidney diseases, obesity, excessive intake of drugs or steroids, and inherited genetic issues. The condition affects men more than women. People with FSGS may also gain weight due to high blood fat levels. Furthermore, they may experience low appetite, exhaustion, and the accumulation of extra fluid in the body.

A combination of imaging studies and laboratory tests are usually used to diagnose FSGS. CT scan or ultrasound helps in detecting any abnormalities and impairment in the kidneys.

Laboratory tests are performed to check the levels of high creatinine, while a urine test helps diagnose proteinuria. Additionally, renal biopsy may be necessary to confirm FSGS in patients. This procedure involves taking a small sample of the kidney with a specific needle and examining it under a microscope.

Increase in Prevalence of Kidney Infection Fueling Focal Segmental Glomerulosclerosis Market Demand

Kidney infection is a type of urinary tract infection (UTI) that may begin in a different part of the urinary tract, such as the urethra (tube that carries urine from the body) or bladder, and travel to one or both kidneys.

According to the Centers for Disease Control and Prevention (CDC), approximately 37 million U.S. adults, or 14% of the adult population, are estimated to have chronic kidney disease (CKD). CKD prevalence increases substantially with age, affecting around 6% of adults aged 18 to 44 years, 13% of those aged 45 to 64 years, and 34% of adults aged 65 years and older. The substantial burden of CKD and other underlying kidney disorders is increasing the need for effective diagnosis and treatment of progressive renal diseases. Consequently, the growing prevalence of chronic kidney disorders is expected to support demand for therapies targeting focal segmental glomerulosclerosis (FSGS) and contribute to market growth.

Rise in Healthcare Expenditure Boosting Market Progress

Growth in spending capacity on healthcare is aiding in the creation and accessibility of medications for focal segmental glomerulosclerosis. Rise in funding for clinical trials and research, which enhance the production of new drugs, is also augmenting the focal segmental glomerulosclerosis industry.

According to the Office for National Statistics (ONS), total healthcare expenditure in the U.K. reached approximately £317 billion (US$430 billion) in 2024, representing a 6.5% increase in nominal terms and a 2.4% increase in real terms compared with 2023. Government-financed healthcare accounted for the majority of spending, reaching approximately £258 billion in 2024. Additionally, total pharmaceutical expenditure in the U.K. was estimated at £35.9 billion in 2023 (at 2024 prices), reflecting the continued importance of medicines within healthcare spending. The sustained increase in healthcare expenditure, rising investment in pharmaceutical therapies, and growing focus on advanced treatments for chronic and rare kidney disorders are expected to support the adoption of targeted therapies for focal segmental glomerulosclerosis (FSGS).

Thus, increase in healthcare spending is creating lucrative focal segmental glomerulosclerosis market opportunities for companies operating in the sector.

Regional Outlook

As per the latest focal segmental glomerulosclerosis market analysis, North America accounted for the largest share in 2025. Presence of developed economies, availability of modern medical facilities, and surge in adoption of high-end technology are driving the growth of the focal segmental glomerulosclerosis industry in the region.

According to recent epidemiological estimates, the U.S. represents the largest market for focal segmental glomerulosclerosis (FSGS) in North America due to the significant diagnosed patient population and higher disease awareness. FSGS is estimated to affect approximately 40,000 people in the U.S., highlighting a substantial unmet medical need among patients with progressive kidney disease. Recent real-world evidence studies estimated the annual standardized prevalence of FSGS in the U.S. at approximately 212.6 cases per million population during 2016-2020, with prevalence increasing over the study period. The rising disease burden, particularly among high-risk populations, along with the introduction of targeted therapies, is expected to strengthen the U.S. FSGS treatment market.

Ongoing clinical trials by manufacturers and rise in research activities are anticipated to spur the market dynamics of North America. Majority of manufacturers worldwide are opting to conduct clinical trials and research in the U.S. owing to the favorable geographical position and governmental policies in the country.

Analysis of Key Players

Increase in investment in research and development activities is a prominent focal segmental glomerulosclerosis marketing strategy adopted by the leading players in the global landscape. Key players are also entering into partnership and collaboration agreements to expand their product portfolio.

Variant Pharmaceuticals, Inc., ChemoCentryx, Inc., Travere Therapeutics, AbbVie, Inc., Novartis AG, Pfizer, Inc., AstraZeneca plc., Sanofi S.A., GlaxoSmithKline plc., are Teva Pharmaceutical Industries Ltd. are the leading players operating in the global landscape.

Each of these firms have been profiled in the focal segmental glomerulosclerosis market report based on parameters such as company overview, business strategies, financial overview, business segments, product portfolio, and recent developments.

Key Developments

In April 2026, Travere Therapeutics received FDA approval for FILSPARI® (sparsentan) for the treatment of focal segmental glomerulosclerosis (FSGS), becoming the first FDA-approved disease-specific therapy for FSGS. The approval was supported by results from the Phase III DUPLEX study, which demonstrated reductions in proteinuria and preservation of kidney function indicators compared with irbesartan. This milestone marked a significant shift in the FSGS treatment landscape, which historically relied on supportive care and off-label immunosuppressive therapies.
In 2025, Vertex Pharmaceuticals advanced its kidney disease pipeline through clinical development of povetacicept (ALPN-303), a dual BAFF/APRIL inhibitor being investigated for autoimmune kidney diseases, including IgA nephropathy and other immune-mediated renal disorders. The advancement of complement and immune pathway-targeted therapies highlights the increasing focus on precision medicine approaches for progressive kidney diseases, including conditions with overlapping disease mechanisms with FSGS.
In 2025, Otsuka Pharmaceutical continued development and commercialization efforts in rare kidney diseases through its nephrology portfolio, focusing on targeted therapies for progressive proteinuric kidney disorders. Increasing investments by large pharmaceutical companies in rare renal disease therapies are contributing to a broader competitive pipeline beyond traditional supportive treatments.

Focal Segmental Glomerulosclerosis Market Snapshot

Attribute	Detail
Market Size in 2025	US$ 1.2 Bn
Market Forecast (Value) in 2036	US$ 2.3 Bn
Growth Rate (CAGR)	5.8%
Forecast Period	2026-2036
Historical Data Available for	2021-2025
Quantitative Units	US$ Bn for Value
Market Analysis	It includes segment analysis as well as regional-level analysis. Furthermore, the qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces Analysis, value chain analysis, and key trend analysis.
Competition Landscape	Market share analysis by company (2025) Company profiles section includes an overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy and recent developments, and key financials
Format	Electronic (PDF) + Excel
Market Segmentation	Disease Type Primary Focal Segmental Glomerulosclerosis Secondary Focal Segmental Glomerulosclerosis Disease Management Diagnosis Kidney Biopsy Creatinine Test Others Treatment Drug Therapy Dialysis Kidney Transplant
Regions Covered	North America Latin America Europe Asia Pacific Middle East & Africa
Countries Covered	U.S. Canada Germany U.K. France Spain Italy Japan China India Australia & New Zealand Brazil Mexico GCC Countries South Africa
Companies Profiled	Variant Pharmaceuticals, Inc. ChemoCentryx, Inc. Travere Therapeutics AbbVie, Inc. Novartis AG Pfizer, Inc. AstraZeneca plc. Sanofi S.A. GlaxoSmithKline plc. Teva Pharmaceutical Industries Ltd. Other Players
Customization Scope	Available upon request
Pricing	Available upon request

Frequently Asked Questions

How big was the focal segmental glomerulosclerosis market in 2025?

It was valued at US$ 1.2 Bn in 2025

How is the focal segmental glomerulosclerosis business expected to grow by 2036?

It is anticipated to grow at a CAGR of 5.8% from 2026 to 2036

What are the key factors driving the demand for focal segmental glomerulosclerosis?

Increase in prevalence of kidney infection and rise in healthcare expenditure

Which was the largest disease type segment in the largest focal segmental glomerulosclerosis industry in 2025?

The primary focal segmental glomerulosclerosis segment accounted for the largest share in 2025

Which was the major region in the global focal segmental glomerulosclerosis landscape in 2025?

North America was the leading region in 2025

Who are the key players in the focal segmental glomerulosclerosis field?

Variant Pharmaceuticals, Inc., ChemoCentryx, Inc., Travere Therapeutics, AbbVie, Inc., Novartis AG, Pfizer, Inc., AstraZeneca plc., Sanofi S.A., GlaxoSmithKline plc., and Teva Pharmaceutical Industries Ltd.

Preface
- Market Definition and Scope
- Market Segmentation
- Key Research Objectives
- Research Highlights
Assumptions and Research Methodology
Executive Summary: Global Focal Segmental Glomerulosclerosis Market
Market Overview
- Introduction
  - Segment Definition
  - Industry Evolution/Developments
- Overview
- Market Dynamics
  - Drivers
  - Restraints
  - Opportunities
- Global Focal Segmental Glomerulosclerosis Market Analysis and Forecast, 2021-2036
Key Insights
- Pipeline Analysis
- Key Disease Type/Brand Analysis
- Key Mergers & Acquisitions
- COVID-19 Pandemic Impact on Industry
Global Focal Segmental Glomerulosclerosis Market Analysis and Forecast, by Disease Type
- Introduction & Definition
- Key Findings/Developments
- Market Value Forecast, by Disease Type, 2021-2036
  - Primary Focal Segmental Glomerulosclerosis
  - Secondary Focal Segmental Glomerulosclerosis
- Market Attractiveness Analysis, by Disease Type
Global Focal Segmental Glomerulosclerosis Market Analysis and Forecast, by Disease Management
- Introduction & Definition
- Key Findings/Developments
- Market Value Forecast, by Disease Management, 2021-2036
  - Diagnosis
    - Kidney Biopsy
    - Creatinine Test
    - Others
  - Treatment
    - Drug Therapy
    - Dialysis
    - Kidney Transplant
- Market Attractiveness Analysis, by Disease Management
Global Focal Segmental Glomerulosclerosis Market Analysis and Forecast, by Region
- Key Findings
- Market Value Forecast, by Region, 2021-2036
  - North America
  - Europe
  - Asia Pacific
  - Latin America
  - Middle East & Africa
- Market Attractiveness Analysis, by Region
North America Focal Segmental Glomerulosclerosis Market Analysis and Forecast
- Introduction
- Key Findings
- Market Value Forecast, by Disease Type, 2021-2036
  - Primary Focal Segmental Glomerulosclerosis
  - Secondary Focal Segmental Glomerulosclerosis
- Market Value Forecast, by Disease Management, 2021-2036
  - Diagnosis
    - Kidney Biopsy
    - Creatinine Test
    - Others
  - Treatment
    - Drug Therapy
    - Dialysis
    - Kidney Transplant
- Market Value Forecast, by Country, 2021-2036
  - U.S.
  - Canada
- Market Attractiveness Analysis
  - By Disease Type
  - By Disease Management
  - By Country
Europe Focal Segmental Glomerulosclerosis Market Analysis and Forecast
- Introduction
- Key Findings
- Market Value Forecast, by Disease Type, 2021-2036
  - Primary Focal Segmental Glomerulosclerosis
  - Secondary Focal Segmental Glomerulosclerosis
- Market Value Forecast, by Disease Management, 2021-2036
  - Diagnosis
    - Kidney Biopsy
    - Creatinine Test
    - Others
  - Treatment
    - Drug Therapy
    - Dialysis
    - Kidney Transplant
- Market Value Forecast, by Country/Sub-region, 2021-2036
  - Germany
  - U.K.
  - France
  - Italy
  - Spain
  - Rest of Europe
- Market Attractiveness Analysis
  - By Disease Type
  - By Disease Management
  - By Country/Sub-region
Asia Pacific Focal Segmental Glomerulosclerosis Market Analysis and Forecast
- Introduction
- Key Findings
- Market Value Forecast, by Disease Type, 2021-2036
  - Primary Focal Segmental Glomerulosclerosis
  - Secondary Focal Segmental Glomerulosclerosis
- Market Value Forecast, by Disease Management, 2021-2036
  - Diagnosis
    - Kidney Biopsy
    - Creatinine Test
    - Others
  - Treatment
    - Drug Therapy
    - Dialysis
    - Kidney Transplant
- Market Value Forecast, by Country/Sub-region, 2021-2036
  - China
  - Japan
  - India
  - Australia & New Zealand
  - Rest of Asia Pacific
- Market Attractiveness Analysis
  - By Disease Type
  - By Disease Management
  - By Country/Sub-region
Latin America Focal Segmental Glomerulosclerosis Market Analysis and Forecast
- Introduction
- Key Findings
- Market Value Forecast, by Disease Type, 2021-2036
  - Primary Focal Segmental Glomerulosclerosis
  - Secondary Focal Segmental Glomerulosclerosis
- Market Value Forecast, by Disease Management, 2021-2036
  - Diagnosis
    - Kidney Biopsy
    - Creatinine Test
    - Others
  - Treatment
    - Drug Therapy
    - Dialysis
    - Kidney Transplant
- Market Value Forecast, by Country/Sub-region, 2021-2036
  - Brazil
  - Mexico
  - Rest of Latin America
- Market Attractiveness Analysis
  - By Disease Type
  - By Disease Management
  - By Country/Sub-region
Middle East & Africa Focal Segmental Glomerulosclerosis Market Analysis and Forecast
- Introduction
- Key Findings
- Market Value Forecast, by Disease Type, 2021-2036
  - Primary Focal Segmental Glomerulosclerosis
  - Secondary Focal Segmental Glomerulosclerosis
- Market Value Forecast, by Disease Management, 2021-2036
  - Diagnosis
    - Kidney Biopsy
    - Creatinine Test
    - Others
  - Treatment
    - Drug Therapy
    - Dialysis
    - Kidney Transplant
- Market Value Forecast, by Country/Sub-region, 2021-2036
  - GCC Countries
  - South Africa
  - Rest of Middle East & Africa
- Market Attractiveness Analysis
  - By Disease Type
  - By Disease Management
  - By Country/Sub-region
Competition Landscape
- Market Player - Competitive Matrix (by Tier and Size of Companies)
- Market Share Analysis, by Company (2025)
- Company Profiles
  - Variant Pharmaceuticals, Inc.
    - Company Overview
    - Disease Type Portfolio
    - SWOT Analysis
    - Financial Overview
    - Strategic Overview
  - ChemoCentryx, Inc.
    - Company Overview
    - Disease Type Portfolio
    - SWOT Analysis
    - Financial Overview
    - Strategic Overview
  - Travere Therapeutics
    - Company Overview
    - Disease Type Portfolio
    - SWOT Analysis
    - Financial Overview
    - Strategic Overview
  - AbbVie, Inc.
    - Company Overview
    - Disease Type Portfolio
    - SWOT Analysis
    - Financial Overview
    - Strategic Overview
  - Novartis AG
    - Company Overview
    - Disease Type Portfolio
    - SWOT Analysis
    - Financial Overview
    - Strategic Overview
  - Pfizer, Inc.
    - Company Overview
    - Disease Type Portfolio
    - SWOT Analysis
    - Financial Overview
    - Strategic Overview
  - AstraZeneca plc.
    - Company Overview
    - Disease Type Portfolio
    - SWOT Analysis
    - Financial Overview
    - Strategic Overview
  - Sanofi S.A.
    - Company Overview
    - Disease Type Portfolio
    - SWOT Analysis
    - Financial Overview
    - Strategic Overview
  - GlaxoSmithKline plc
    - Company Overview
    - Disease Type Portfolio
    - SWOT Analysis
    - Financial Overview
    - Strategic Overview
  - Teva Pharmaceutical Industries Ltd.
    - Company Overview
    - Disease Type Portfolio
    - SWOT Analysis
    - Financial Overview
    - Strategic Overview

List of Figures

Figure 01: Global Focal Segmental Glomerulosclerosis Market Size (US$ Mn) and Distribution (%), by Region, 2025 and 2036
Figure 02: Global Focal Segmental Glomerulosclerosis Market Revenue (US$ Mn), by Disease Type, 2025
Figure 03: Global Focal Segmental Glomerulosclerosis Market Value Share, by Disease Type, 2025
Figure 04: Global Focal Segmental Glomerulosclerosis Market Revenue (US$ Mn), by Disease Management, 2025
Figure 05: Global Focal Segmental Glomerulosclerosis Market Value Share, by Disease Management, 2025
Figure 06: Global Focal Segmental Glomerulosclerosis Market Value Share, by Region, 2025
Figure 07: Global Focal Segmental Glomerulosclerosis Market Value (US$ Mn) Forecast, 2021 to 2036
Figure 08: Global Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Type, 2025 and 2036
Figure 09: Global Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Disease Type, 2026-2036
Figure 10: Global Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Management, 2025 and 2036
Figure 11: Global Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Disease Management, 2026-2036
Figure 12: Global Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Region, 2025 and 2036
Figure 13: Global Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Region, 2026-2036
Figure 14: North America Focal Segmental Glomerulosclerosis Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2021 to 2036
Figure 15: North America Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Country, 2026 to 2036
Figure 16: North America Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Country, 2025 and 2036
Figure 17: North America Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Type, 2025 and 2036
Figure 18: North America Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Management, 2025 and 2036
Figure 19: North America Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Disease Type, 2026 to 2036
Figure 20: North America Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Disease Management, 2026 to 2036
Figure 21: Europe Focal Segmental Glomerulosclerosis Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2021 to 2036
Figure 22: Europe Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Country/Sub-region, 2026 to 2036
Figure 23: Europe Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Country/Sub-region, 2025 and 2036
Figure 24: Europe Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Type, 2025 and 2036
Figure 25: Europe Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Management, 2025 and 2036
Figure 26: Europe Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Disease Type, 2026 to 2036
Figure 27: Europe Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Disease Management, 2026 to 2036
Figure 28: Asia Pacific Focal Segmental Glomerulosclerosis Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2021 to 2036
Figure 29: Asia Pacific Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Country/Sub-region, 2026 to 2036
Figure 30: Asia Pacific Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Country/Sub-region, 2025 and 2036
Figure 31: Asia Pacific Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Type, 2025 and 2036
Figure 32: Asia Pacific Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Management, 2025 and 2036
Figure 33: Asia Pacific Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Disease Type, 2026-2036
Figure 34: Asia Pacific Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Disease Management, 2026 to 2036
Figure 35: Latin America Focal Segmental Glomerulosclerosis Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2021 to 2036
Figure 36: Latin America Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Country/Sub-region, 2026 to 2036
Figure 37: Latin America Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Country/Sub-region, 2025 and 2036
Figure 38: Latin America Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Type, 2025 and 2036
Figure 39: Latin America Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Management, 2025 and 2036
Figure 40: Latin America Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Disease Type, 2026 to 2036
Figure 41: Latin America Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Disease Management, 2026 to 2036
Figure 42: Middle East & Africa Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2021 to 2036
Figure 43: Middle East & Africa Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Country/Sub-region, 2026 to 2036
Figure 44: Middle East & Africa Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Country/Sub-region, 2025 and 2036
Figure 45: Middle East & Africa Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Type, 2025 and 2036
Figure 46: Middle East & Africa Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Management, 2025 and 2036
Figure 47: Middle East & Africa Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Disease Type, 2026 to 2036
Figure 48: Middle East & Africa Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Disease Management, 2026 to 2036

List of Tables

Table 01: Global Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Type, 2021 to 2036
Table 02: Global Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Management, 2021 to 2036
Table 03: Global Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Region, 2021 to 2036
Table 04: North America Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Country, 2021 to 2036
Table 05: North America Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Type, 2021 to 2036
Table 06: North America Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Management, 2021 to 2036
Table 07: Europe Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Country/Sub-region, 2021 to 2036
Table 8: Europe Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Type, 2021 to 2036
Table 9: Europe Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Management, 2021 to 2036
Table 10: Asia Pacific Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Country/Sub-region, 2021 to 2036
Table 11: Asia Pacific Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Type, 2021 to 2036
Table 12: Asia Pacific Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Management, 2021 to 2036
Table 13: Latin America Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Country/Sub-region, 2021 to 2036
Table 14: Latin America Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Type, 2021 to 2036
Table 15: Latin America Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Management, 2021 to 2036
Table 16: Middle East & Africa Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Country/Sub-region, 2021 to 2036
Table 17: Middle East & Africa Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Type, 2021 to 2036
Table 18: Middle East & Africa Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Management, 2021 to 2036